MedTrace Logo

Atherothrombosis Markers in Diabetics

NCT02898467 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2016-09-13

No results posted yet for this study

Summary

Intraplaque hemorrhage is the driving force of atherothrombotic plaque vulnerability to rupture and associated clinical complications. Polymorphonuclear neutrophils (PMNs) represent about 70% of leukocytes and may constitute a source of proteases and oxidants that favour plaque rupture. Our objective is to evaluate PMN activation in atherosclerotic plaque of non-diabetic versus type 2 diabetic patients. For this purpose, investigators will quantify the presence of cell-free DNA, that reflect the formation of neutrophil extracellular traps (NETs) in carotid endarterectomy samples.

Conditions

Interventions

OTHER

diabetics

additional blood and urine collection during usual medical care endarterectomy samples during usual medical care

OTHER

non-diabetics

additional blood and urine collection during usual medical care endarterectomy samples during usual medical care

Sponsors & Collaborators

  • Academic Health Science Centres

    collaborator OTHER

  • Centre Hospitalier Universitaire de la Réunion

    lead OTHER

Principal Investigators

  • XAVIER DEBUSSCHE, MD · CHU DE LA REUNION

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-31
Primary Completion
2018-11-30
Completion
2019-06-30

Countries

  • France

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02898467 on ClinicalTrials.gov